Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Galel, D. Strong, G. Tegtmeier, P. Holland, I. Kuramoto, M. Kemper, L. Pietrelli, J. Gallarda (2002)
Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assaysTransfusion, 42
Barbara Peoples, S. Preston, J. Tzeng, S. Stramer, L. Gifford, M. Wissel (2000)
Prolonged antibody‐negative HCV viremia in a US blood donor with apparent HCV transmission to a recipientTransfusion, 40
D. Marshall, S. Kleinman, J. Wong, J. AuBuchon, D. Grima, N. Kulin, M. Weinstein (2004)
Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United StatesVox Sanguinis, 86
R. Dodd, E. Notari, S. Stramer (2002)
Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor populationTransfusion, 42
M. Busch (2001)
Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 8 3
L. Pealer, A. Marfin, L. Petersen, R. Lanciotti, P. Page, S. Stramer, M. Stobierski, K. Signs, B. Newman, H. Kapoor, J. Goodman, M. Chamberland (2003)
Transmission of West Nile virus through blood transfusion in the United States in 2002.The New England journal of medicine, 349 13
C. Giachetti, J. Linnen, D. Kolk, J. Dockter, K. Gillotte-Taylor, M. Park, Martha Ho-Sing-Loy, M. McCormick, L. Mimms, S. Mcdonough (2002)
Highly Sensitive Multiplex Assay for Detection of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus RNAJournal of Clinical Microbiology, 40
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Low Levels of Hepatitis C Virus RNA in Serum, Plasma, and Peripheral Blood Mononuclear Cells of Injecting Drug Users During Long Antibody-Undetectable Periods Before Seroconversion
W. Schmidt, P. Wu, J. Cederna, F. Mitros, D. Labrecque, J. Stapleton (1997)
Surreptitious hepatitis C virus (HCV) infection detected in the majority of patients with cryptogenic chronic hepatitis and negative HCV antibody tests.The Journal of infectious diseases, 176 1
R. Dodd (2003)
Emerging infections, transfusion safety, and epidemiology.The New England journal of medicine, 349 13
(2004)
West Nile virus screening of blood donations and transfusion - associated transmission — United States , 2003
E. Fiebig, D. Wright, B. Rawal, P. Garrett, R. Schumacher, L. Peddada, C. Heldebrant, Richard Smith, A. Conrad, S. Kleinman, M. Busch (2003)
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infectionAIDS, 17
P. Grant, M. Busch (2002)
Nucleic acid amplification technology methods used in blood donor screeningTransfusion Medicine, 12
Jennie Orland, T. Wright, S. Cooper (2001)
Acute hepatitis CHepatology, 33
P. Maple, T. McKee, U. Desselberger, T. Wreghitt (1994)
Hepatitis C virus infections in transplant patients: Serological and virological investigationsJournal of Medical Virology, 44
M. Busch, S. Kleinman, G. Nemo (2003)
Current and emerging infectious risks of blood transfusions.JAMA, 289 8
R. Janssen, G. Satten, S. Stramer, B. Rawal, T. O'Brien, B. Weiblen, F. Hecht, N. Jack, F. Cleghorn, J. Kahn, M. Chesney, M. Busch (1998)
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes.JAMA, 280 1
Sharyn Orton, S. Stramer, R. Dodd, M. Alter (2004)
Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti‐HCVTransfusion, 44
B. Jackson, M. Busch, S. Stramer, J. AuBuchon (2003)
The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donationsTransfusion, 43
G. Schreiber, M. Busch, S. Kleinman, J. Korelitz (1996)
The Risk of Transfusion-Transmitted Viral InfectionsThe New England Journal of Medicine, 334
M. Busch, S. Stramer (1998)
The Efficiency of HIV p24 Antigen Screening of US Blood Donors: Projections versus RealityTransfusion Medicine and Hemotherapy, 25
L. Tobler, M. Busch (1997)
History of posttransfusion hepatitis.Clinical chemistry, 43 8 Pt 2
Eric Delwart, Eric Delwart, N. Kalmin, T. Jones, D. Ladd, Brian Foley, L. Tobler, R. Tsui, M. Busch, M. Busch (2004)
First report of human immunodeficiency virus transmission via an RNA‐screened blood donationVox Sanguinis, 86
S. Stramer, S. Caglioti, D. Strong (2000)
NAT of the United States and Canadian blood supplyTransfusion, 40
M. Chamberland (2002)
Emerging infectious agents: do they pose a risk to the safety of transfused blood and blood products?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 34 6
(2004)
Replacement of HIV - 1 p 24 antigen screening with HIV - 1 RNA nucleic acid testing ( NAT ) for whole blood donations
(1981)
Confidence regions : definition and construction in the binomial case
G. Schreiber, S. Glynn, G. Satten, F. Kong, D. Wright, M. Busch, Y. Tu, S. Kleinman (2002)
HIV seroconverting donors delay their return: screening test implicationsTransfusion, 42
M. Busch, S. Kleinman, B. Jackson, S. Stramer, I. Hewlett, S. Preston (2000)
Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors.Transfusion, 40 2
L. Tobler, S. Stramer, Stephen Lee, B. Masecar, J. Peterson, E. Davis, W. Andrews, Jaye Brodsky, S. Kleinman, B. Phelps, M. Busch (2003)
Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood‐donor screeningTransfusion, 43
M. Busch, R. Dodd (2000)
NAT and blood safety: what is the paradigm?Transfusion, 40
M. Alter, W. Kuhnert, L. Finelli (2003)
Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 52 RR-3
E. Notari, Sharyn Orton, R. Cable, A. Grindon, B. Lenes, A. Williams, Kimberly McMillan, J. Trouern‐Trend, Jennifer Wolf‐Nugent, Yiling Xu, R. Dodd (2001)
Seroprevalence of known and putative hepatitis markers inUnited States blood donors with ALT levels at least 120 IU per LTransfusion, 41
(2001)
Closing the windows on viral transmission by blood transfusion
BackgroundTesting of blood donors for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) RNA by means of nucleic acid amplification was introduced in the United States as an investigational screening test in mid-1999 to identify donations made during the window period before seroconversion.MethodsWe analyzed all antibody-nonreactive donations that were confirmed to be positive for HIV-1 and HCV RNA on nucleic acid–amplification testing of “minipools” (pools of 16 to 24 donations) by the main blood-collection programs in the United States during the first three years of nucleic acid screening.ResultsAmong 37,164,054 units screened, 12 were confirmed to be positive for HIV-1 RNA — or 1 in 3.1 million donations — only 2 of which were detected by HIV-1 p24 antigen testing. For HCV, of 39,721,404 units screened, 170 were confirmed to be positive for HCV RNA, or 1 in 230,000 donations (or 1 in 270,000 on the basis of 139 donations confirmed to be positive for HCV RNA with the use of a more sensitive HCV-antibody test). The respective rates of positive HCV and HIV-1 nucleic acid–amplification tests were 3.3 and 4.1 times as high among first-time donors as among donors who gave blood repeatedly. Follow-up studies of 67 HCV RNA–positive donors demonstrated that seroconversion occurred a median of 35 days after the index donation, followed by a low rate of resolution of viremia; three cases of long-term immunologically silent HCV infection were documented.ConclusionsMinipool nucleic acid–amplification testing has helped prevent the transmission of approximately 5 HIV-1 infections and 56 HCV infections annually and has reduced the residual risk of transfusion-transmitted HIV-1 and HCV to approximately 1 in 2 million blood units.
The New England Journal of Medicine – The New England Journal of Medicine
Published: Aug 19, 2004
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.